Tuesday - April 29, 2025

LOGIN  |  REGISTER
Chimerix
Assertio

Astrana Health Announces Share Repurchase of 300,000 Shares

January 21, 2025 | Last Trade: US$31.15 0.41 1.33

ALHAMBRA, Calif., Jan. 21, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that on January 17, 2025, the Company repurchased 300,000 shares of the Company's common stock for the aggregate purchase price of $10.551 million, based on a purchase price per share of $35.17, which was the closing price per share on the Nasdaq Stock Market on such date.

"The share repurchase is a testament to management and the Board of Directors' confidence in the performance of Astrana Health. We remain committed to our strategic capital deployment practices and continue to prioritize long-term growth, including through opportunistic share repurchases," said Brandon K. Sim, President and CEO of Astrana.

The shares were purchased from Allied Physicians of California, a Professional Medical Corporation ("APC"), a long-standing stockholder and a consolidated affiliate of the Company. The Company's Board of Directors and the Audit Committee of the Board of Directors approved the repurchase.

About Astrana Health, Inc.

Astrana is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, Astrana serves over 12,000 providers and over 1.1 million Americans in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), accountable care organizations (ACOs), and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
Asher Dewhurst
investors@astranahealth.com

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page